Top
  • Company
    • Overview
    • Leadership
    • Board of Directors
    • Contact Us
  • Science
    • ST266 Biologic
    • Key Mechanisms to Healing
    • Innovative Delivery Options
    • Scalable Manufacturing
    • Publications
  • Pipeline
    • Current Programs
    • Other Programs
    • Clinical Trials
  • News
    • Press Releases
  • Careers
    • Why Noveome?
    • Hear From Our Employees
    • Pittsburgh Please
    • Competitive Benefits
    • Career Opportunities
  • Company
    • Overview
    • Leadership
    • Board of Directors
    • Contact Us
  • Science
    • ST266 Biologic
    • Key Mechanisms to Healing
    • Innovative Delivery Options
    • Scalable Manufacturing
    • Publications
  • Pipeline
    • Current Programs
    • Other Programs
    • Clinical Trials
  • News
    • Press Releases
  • Careers
    • Why Noveome?
    • Hear From Our Employees
    • Pittsburgh Please
    • Competitive Benefits
    • Career Opportunities

Category: Publication

Amnion-derived cellular cytokine solution (ACCS) promotes migration of keratinocytes and fibroblasts.

Posted on May 5, 2010October 3, 2019 by admin

Uberti, M.G., et al.,

Continue reading “Amnion-derived cellular cytokine solution (ACCS) promotes migration of keratinocytes and fibroblasts.” →

Posted in Publication

Human amnion-derived multipotent progenitor cell treatment alleviates traumatic brain injury-induced axonal degeneration

Posted on November 11, 2009October 3, 2019 by admin

Chen, Z., et al.,

Continue reading “Human amnion-derived multipotent progenitor cell treatment alleviates traumatic brain injury-induced axonal degeneration” →

Posted in Publication

The effect of amnion-derived cellular cytokine solution on the epithelialization of partial-thickness donor site wounds

Posted on October 20, 2009October 3, 2019 by admin

Bergmann, J., et al.,

Continue reading “The effect of amnion-derived cellular cytokine solution on the epithelialization of partial-thickness donor site wounds” →

Posted in Publication

The use of amnion-derived cellular cytokine solution (ACCS) in accelerating closure of interstices in explanted meshed human skin grafts

Posted on March 25, 2009October 3, 2019 by admin

Uberti, M.G., et al.,

Continue reading “The use of amnion-derived cellular cytokine solution (ACCS) in accelerating closure of interstices in explanted meshed human skin grafts” →

Posted in Publication

Immunogenicity and Immunomodulatory effects of amnion-derived multipotent progenitor cells

Posted on June 6, 2008October 3, 2019 by admin

Banas, R.A., et al.,

Continue reading “Immunogenicity and Immunomodulatory effects of amnion-derived multipotent progenitor cells” →

Posted in Publication

The use of Amnion-derived Cellular Cytokine Suspension (ACCS) to improve healing in acute and chronic wounds

Posted on April 11, 2008October 3, 2019 by admin

Franz, M.G., et al.,

Continue reading “The use of Amnion-derived Cellular Cytokine Suspension (ACCS) to improve healing in acute and chronic wounds” →

Posted in Publication

Amnion-derived Cellular Cytokine Solution: a physiological combination of cytokines for wound healing

Posted on April 7, 2008October 3, 2019 by admin

Steed, D.L., et al.,

Continue reading “Amnion-derived Cellular Cytokine Solution: a physiological combination of cytokines for wound healing” →

Posted in Publication

Amnion-derived multipotent progenitor cells increase gain of incisional breaking strength and severity of acute wound failure

Posted on October 5, 2007October 3, 2019 by admin

Xing, L., et al.,

Continue reading “Amnion-derived multipotent progenitor cells increase gain of incisional breaking strength and severity of acute wound failure” →

Posted in Publication

Posts navigation

Newer posts

Recent Posts

  • Noveome Biotherapeutics, Inc. Announces Issuance of U.S. Patent No. 12,121,546 Entitled, “Treatment of Systemic Inflammatory Responses”
  • Noveome Biotherapeutics, Inc. Announces Completion of Treatment of the First Baby in its Phase 1-2 Clinical Trial Evaluating ST266 in the Treatment of Necrotizing Enterocolitis in Premature Infants
  • Noveome Biotherapeutics, Inc. Receives FDA Notification to Proceed with its Phase 1-2 Clinical Trial in Treatment of NEC
  • Noveome Biotherapeutics, Inc. Completes First Close of $40 Million Series E Financing to Support Clinical Trials in NEC
  • Noveome Biotherapeutics, Inc. Announces New Appointments to Board of Directors

Recent Comments

    Archives

    • November 2024
    • December 2023
    • August 2023
    • November 2022
    • May 2022
    • January 2022
    • June 2021
    • May 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • October 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • May 2018
    • April 2018
    • January 2018
    • November 2017
    • January 2017
    • November 2015
    • July 2015
    • September 2014
    • August 2014
    • June 2013
    • August 2012
    • August 2011
    • May 2011
    • January 2011
    • July 2010
    • May 2010
    • November 2009
    • October 2009
    • March 2009
    • June 2008
    • April 2008
    • October 2007

    Categories

    • Board of Directors
    • Management
    • Press Release
    • Publication
    • Scientific Advisory Board

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    contact

    +1.412.402.9914

    General inquiries: info@noveome.com

    Clinical inquiries: clinical@noveome.com

    Noveome Biotherapeutics, Inc.

    620 Alpha Drive

    Suite 2

    Pittsburgh, PA 15238

    • Company
    • Science
    • Pipeline
    • News
    • Careers

    privacy policy

    terms of use

    © 2020 Noveome Biotherapeutics, Inc. All rights reserved. Noveome® is a registered trademark of Noveome Biotherapeutics, Inc.